Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

We developed a simple flow cytometry assay for evaluating the binding of PD-1–blocking antibodies to T cells, requiring only a drop of peripheral blood from cancer patients.

Abstract

Immune checkpoint inhibitors, including PD-1–blocking antibodies, have significantly improved treatment outcomes in various types of cancer. The pharmacological efficacy of these immunotherapies is long lasting, extending even beyond the discontinuation of their injections, due to persistent blood concentrations. Here we developed a simple flow cytometry assay to evaluate the T cell binding status of the PD-1–blocking antibodies nivolumab and pembrolizumab. Like a glucose test, this assay requires just a single drop of peripheral blood. Visualizing antibody binding on T cells is more reliable than measuring antibody blood concentrations. In addition, if necessary, we can potentially analyze many distinctive immune-related markers on T cells bound to PD-1–blocking antibodies. Thus, this is a simple and minimally invasive strategy to analyze the pharmacological effect of PD-1–blocking antibodies in cancer patients.

Introduction

PD-1–blocking antibodies have become the standard choice for treatment of various types of cancer, including non-small cell lung cancer (NSCLC)1,2,3,4. They show a remarkable therapeutic effect in a subset of cancer patients who have not responded to conventional cytotoxic chemotherapies. However, immune checkpoint inhibitors (ICIs), which include PD-1–blocking antibodies, can cause a unique and distinct spectrum of adverse events, termed immune-related adverse events (irAEs)5. Although irAEs can affect al....

Protocol

Sampling was performed during routine clinical procedures. All human samples were obtained after informed consent was provided by the subjects, in accordance with the Declaration of Helsinki and with the approval of the ethical review board of the Graduate School of Medicine, Osaka University, Japan (15383 and 752).

1. Whole Blood Sample Preparation and Staining

  1. Collect whole blood samples into blood collection tubes containing ethylene diamine tetra-acetic acid (EDTA).
    NOTE.......

Representative Results

The gating strategy and flow cytometry analysis (Figure 1) can detect PD-1–blocking antibody binding to T cells obtained from a drop of NSCLC patient peripheral blood. Before PD-1–blocking antibody is administered, no human IgG4-positive CD8 or CD4 T cells are present, and PD-1 expression can be confirmed by a PD-1–detecting antibody (EH12.1) (Figure 2A). After nivolumab or pembrolizumab administration, IgG4 (nivolumab, pembrol.......

Discussion

In this article, we report a method using a flow cytometer to detect PD-1–blocking antibodies bound to T cells derived from a drop of peripheral blood, which we originally developed for nivolumab detection10. Although this technique is very simple and easy to perform, two important points should be noted in order to obtain accurate results. One is that to detect PD-1 molecules, an appropriate antibody that competes with nivolumab and pembrolizumab should be used. This issue was evaluated in .......

Acknowledgements

This work was supported by grants to S.K. from the Japan Society for the Promotion of Science KAKENHI (JP17K16045) and the Japan Agency for Medical Research and Development (JP18cm0106335 and 19cm0106310).

....

Materials

NameCompanyCatalog NumberComments
10X RBC Lysis Buffer (Multi-species)Thermo Fisher Scientific00-4300-5450 mL
APC/Cyanine7 anti-human CD4 AntibodyBioLegend300518Clone RPA-T4
BD FACS Canto II Flow CytometerBD
Brilliant Violet 510 anti-human CD8a AntibodyBioLegend301048Clone RPA-T8
Dulbecco's Phosphate Buffered Salinenacalai tesque14249-95500 mL
Falcon Round-Bottom Polystyrene TubesSTEMCELL Technologies3520585 mL
FcR Blocking Reagent, humanMiltenyi Biotec130-059-9012 mL
FLOWJOBD
Gibco Fetal Bovine SerumThermo Fisher Scientific12676029500 mL
Mouse IgG1 monoclonal - Isotype controlabcamab81200
Mouse monoclonal Anti-Human IgG4 Fcabcamab99825Clone HP6025
Pacific Blue Mouse Anti-Human CD3BD558117Clone UCHT1
PE-Cy7 Mouse anti-Human CD279 (PD-1)BD561272Clone EH12.1
PE-Cy7 Mouse IgG1 κ Isotype ControlBD557646

References

  1. Gong, J., Chehrazi-Raffle, A., Reddi, S., Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for ImmunoTherapy of Cancer. 6 (1), 8 (2018).
  2. Borghaei, H., et al.

Explore More Articles

PD 1 blocking AntibodiesT CellsPeripheral BloodFlow CytometryCD8 T CellsCD4 T CellsPD 1Human IgG4Antitumor EffectsImmune related Adverse EventsBlood SampleCell IsolationCell StainingData Analysis

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved